海思科：HSK36357胶囊新适应症IND申请获受理

Core Viewpoint - The company announced that its subsidiary, Shanghai Haisco Shenno Pharmaceutical Technology Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the drug HSK36357 capsules, which are intended for the treatment of muscular dystrophy [1] Group 1 - The drug HSK36357 is a new small molecule developed independently by the company [1] - The clinical application of HSK36357 is aimed at treating muscular dystrophy, including Becker muscular dystrophy and Duchenne muscular dystrophy [1] - The acceptance numbers for the clinical trial registration are CXHL2501059 and CXHL2501060 [1]